Effects of combined administration of rapamycin, tolvaptan, and AEZ-131 on the progression of polycystic disease in PCK rats

American Journal of Physiology - Renal Physiology

Volumn 306, Issue 10, 2014, Pages

  Sabbatini, Massimo ^a   Russo, Luigi ^a   Cappellaio, Francesco ^a   Troncone, Giancarlo ^a   Bellevicine, Claudio ^a   De Falco, Valentina ^a   Buonocore, Preziosa ^a   Riccio, Eleonora ^a   Bisesti, Vincenzo ^a   Federico, Stefano ^a   Pisani, Antonio ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Cyst volume density; Extracellular signalregulated kinase inhibitors; Polycystic kidney disease; Rapamycin; Tolvaptan

Indexed keywords

AEZ 131; BINDING PROTEIN; CYCLIC AMP; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; RAPAMYCIN; TOLVAPTAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; IMMUNOBLOTTING; KIDNEY POLYCYSTIC DISEASE; LOW DRUG DOSE; MALE; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; RAT; URINARY EXCRETION; WEIGHT GAIN;

CYST VOLUME DENSITY; EXTRACELLULAR SIGNAL-REGULATED KINASE INHIBITORS; POLYCYSTIC KIDNEY DISEASE; RAPAMYCIN; TOLVAPTAN;

ANIMALS; BENZAZEPINES; CYCLIC AMP; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; KIDNEY; MALE; MAP KINASE SIGNALING SYSTEM; POLYCYSTIC KIDNEY DISEASES; RATS; RATS, INBRED STRAINS; RATS, MUTANT STRAINS; RATS, SPRAGUE-DAWLEY; SIROLIMUS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84900831081     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00694.2013     Document Type: Article

References (40)

1. Bahr V, Franzen N, Oelkers W, Pfeiffer A, Diederich S. Effect of exogenous glucocorticoid on osmotically stimulated antidiuretic hormone secretion and on water reabsorption in man. Eur J Endocrinol 155: 845-848, 2006.
2. Benson C, White J, Bono JD, O'Donnell A, Raynaud F, Cruickshank C, McGrath H, Walton M, Workman P, Kaye S, Cassidy J, Gianella-Borradori A, Judson I, Twelves C. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer 96: 29-37, 2007.
3. Blonde L, Wehmann RE, Steiner AL. Plasma clearance rates and renal clearance of 3H-labeled cyclic AMP and 3H-labeled cyclic GMP in the dog. J Clin Invest 53: 163-172, 1974.
4. Boyce RW, Dorph-Petersen KA, Gundersen HG. Design-based stereology: introduction to basic concepts and practical approaches for estimation of cell number. Toxicol Pathol 38: 1011-1025, 2010.
5. Buchholz B, Klanke B, Schley G, Bollag G, Tsai J, Kroening S, Yoshihara D, Wallace DP, Kraenzlin B, Gretz N, Hirth P, Eckardt KU, Bernhardt WM. The Raf kinase inhibitor PLX5568 slows cyst proliferation in rat polycystic disease but promotes renal and hepatic fibrosis. Nephrol Dial Transplant 26: 3458-3465, 2011.
6. Bukanov NO, Smith LA, Klinger KW, Ledbetter SR, Ibraghimov-Beskrovnaya O. Lomg-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine. Nature 444: 949-952, 2006.
7. Calvet JP. MEK inhibition holds promise for polycystic kidney disease. J Am Soc Nephrol 17: 1498-1500, 2006.
8. Caroli A, Perico N, Perna A, Antiga L, Brambilla P, Pisani A, Visciano B, Imbriaco M, Messa P, Cerutti R, Dugo M, Cancian L, Buongiorno E, De Pascalis A, Gaspari F, Carrara F, Rubis N, Prandini S, Remuzzi A, Remuzzi G, Ruggenenti P. Effect of longacting somatostatin analog on kidney and cyst growth in autosomal polycystic kidney disease (ALADIN): a randomised, placebo-controlled, mulicentre trial. Lancet 382: 1485-1495, 2013.
9. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, Papa A, Nardella C, Cantley LC, Baselga J, Pandolfi PP. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118: 3065-3074, 2008.
10. Chrispijn M, Gevers TG, Hol JC, Monshouwer R, Dekker HM, Drenth JP. Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial. J Hepatol 59: 153-159, 2013.
11. Cowley BD Jr, Rupp JC, Muessel MJ, Gattone VH. Gender and the effect of gonadal hormones on the progression of inherited polycystic kidney disease in rats. Am J Kidney Dis 29: 265-272, 1997.
12. De Falco V, Buonocore P, Muthu M, Torregrossa L, Basolo F, Billaud M, Gozgit JM, Carlomagno F, Santoro M. Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer. J Clin Endocrinol Metab 98: E811-E819, 2013.
13. Gattone VH, Wang X, Harris PC, Torres VE. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 9: 1323-6, 2003.
14. Gattone VH, Sindels RM, Hornberger TA, Robling AG. Late progression of renal pathology and cyst enlargement is reduced by rapamycin in a mouse model of nephronophtisis. Kidney Int 76: 178-182, 2009.
15. Grantham JJ. Polycystic kidney disease: neoplasia in disguise. Am J Kidney Dis 15: 110-116, 1990.
16. Gundersen HJ, Jensen EB. The efficiency of systematic sampling in stereology and its prediction. J Microsc 147: 229-263, 1987.
17. Lager DJ, Qian QI, Benga RJ, Ishibashi M, Torres VE. The pck rat: a new model that resembles human autosomal dominant polycystic kidney and liver disease. Kidney Int 59: 126-136, 2001.
18. Legrier ME, Yang CH, Yan H, Lopez-Barcons L, Keller SM, Perez-Soler R, Horwitz SB, McDaid HM. Targeting protein translation in human non-small cell lung cancer via combined MEK and mammalian target of rapamycin suppression. Cancer Res 67: 11300-11308, 2007.
19. Masyuk TV, Masyuk AI, Torres VE, Harris PC, Larusso NF. Octreotide inhibits hepatic cystogenesis, in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3′,5′-cyclic monophosphate. Gastroenterology 132: 1104-1116, 2007.
20. Meijer E, Drenth JP, D'Agnolo H, Casteleijn NF, de Fijter JW, Gevers TJ, Kappert P, Peters DJ, Salih M, Soonawala D, Spithoven EM, Torres VE, Visser FW, Wetzels JF, Zietse R, Gansevoort RT; DIPAK Consortium. Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to halt disease progression in autosomal dominant polycystic kidney disease. Am J Kidney Dis 63: 446-455, 2014.
21. Nagao S, Yamaguchi T, Kusaka M, Maser RL, Takahashi H, Cowley BD, Grantham JJ. Renal activation of extracellular signal-regulated kinase in rats with autosomal-dominant polycystic kidney disease. Kidney Int 63: 427-437, 2003.
22. Omori S, Hida M, Fujita H, Takahashi H, Tanimura S, Kohono M, Awazu M. Extracellular signal-regulated kinase inhibition slows disease progression in mice with polycystic kidney disease. J Am Soc Nephrol 17: 1604-1614, 2006.
23. Priolo C, Henske EP. Metabolic reprogramming in polycystic kidney disease. Nat Med 19: 407-409, 2013.
24. - secretion, and in vitro cyst growth in human ADPKD cells stimulated by vasopressin. Am J Physiol Renal Physiol 301: F1005-F1013, 2011.
25. Renken C, Fischer DC, Kundt G, Gretz N, Haffner D. Inhibition of mTOR with sirolimus does not attenuate progression of liver and kidney disease in PCK rats. Nephrol Dial Transplant 26: 92-100, 2011.
26. Rowe I, Chiaravalli M, Mannella V, Ulisse V, Quilici G, Pema M, Song XW, Xu H, Mari S, Qian F, Peoi Y, Musco G, Boletta A. Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy. Nat Med 19: 488-494, 2013.
27. Sabbatini M, Santillo M, Pisani A, Paternò R, Uccello F, Serù R, Matrone G, Spagnuolo G, Andreucci M, Serio V, Esposito P, Cianciaruso B, Fuiano G, Avvedimento EV. Inhibition of Ras/ERK1/2 signaling protects against postischemic renal injury. Am J Physiol Renal Physiol 290: F1408-F1415, 2006.
28. Sabbatini M, Russo L, Uccello F, Iaccarino A, Pisani A. Clinical treatment of polycystic kidney disease (APKD): do we need further suggestions from rodents? Nephrol Dial Transplant 26: 2065-2066, 2011.
29. Saini KS, Loi S, de Azambuja E, Metzger-Filho O, Saini ML, Ignatiadis M, Dancey JE, Piccart-Gebhart MJ. Targeting the PI3K/AKT/ mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. Cancer Treat Rev 39: 935-946, 2013.
30. Serra AL, Poster D, Kistler AD, Krauer F, Raina S, Young J, Rentsch KM, Spanaus KS, Senn O, Kristanto P, Scheffel H, Weishaupt D, Wüthrich RP. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 363: 820-829, 2010.
31. Shillingford JM, Murcia NS, Larson CH, Low SH, Hedgepeth R, Brown N, Flask CA, Novick AC, Goldfarb DA, Kramer-Zucker A, Walz G, Piontek KB, Germino GG T, Weimbs T. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci USA 103: 5466-5471, 2006.
32. Stallone G, Infante B, Grandaliano G, Bristogiannis C, Macarini L, Mezzopane D, Bruno F, Montemurno E, Schirinzi A, Sabbatini M, Pisani A, Tataranni T, Schena FP, Gesualdo L. Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYDstudy): a randomized, controlled study. Nephrol Dial Transplant 27: 3560-3567, 2012.
33. Tao Y, Schrier RW, Edelstein CL. Rapamycin markedly slows disease progression in a rat model of polycistic kidney disease. J Am Soc Nephrol 16: 46-51, 2005.
34. Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH. Effective treatment of an orthologous model of autosomal polycystic kidney disease. Nat Med 10: 363-364, 2004.
35. Torres VE, Harris PC. Polycistic kidney disease: genes proteins, animal models, disease mechanisms and therapeutic opportunities. J Intern Med 261: 17-31, 2007.
36. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS; TEMPO 3:4 Trial Investigators. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367: 2407-2418, 2012.
37. Wahl PR, Serra AL, Le Hir M, Molle KD, Hall MN, Wuthrich RP. Inhibition of mTOR with sirolimus slows disease progression in Han: SPRD rats with autosomal dominant polycystic kidney ddisease (ADPKD). Nephrol Dial Transplant 21: 598-604, 2006.
38. Walz G, Budde K, Mannaa M, Nürnberger J, Wanner C, Sommerer C, Kunzendorf U, Banas B, Hörl WH, Obermüller N, Arns W, Pavenstädt H, Gaedeke J, Büchert M, May C, Gschaidmeier H, Kramer S, Eckardt KU. Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 363: 830-840, 2010.
39. Wang X, Gattone VII, Harris PC, Torres VE. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol 16: 846-851, 2005.
40. Yamamura Y, Nakamura S, Itoh S, Hirano T, Onogawa T, Yamashita T, Yamada Y, Tsujimae K, Aoyama M, Kotosai K, Ogawa H, Yamashita H, Kondo K, Tominaga M, Tsujimoto G, Mori T. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exper Ther 287: 860-867, 1998.